Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From resTORbio, Inc.
Finance Watch: Biopharma IPOs Slow But SPACs Back On The Go
Public Company Edition: It has been almost a month since a biopharma firm launched an IPO in the US, but special purpose acquisition corporations continue to take drug makers public, including Alvotech and Aerami. Outside the US, MaaT closed an IPO in Paris and BeiGene priced a Shanghai offering.
Deal Watch: Menarini Enters US Oncology Market Via Merger With Stemline
Menarini/Stemline, Supernus/US WorldMeds, BioMarin/DiNOAQOR, Adicet/ResTORbio, Vertex/Affinia, Hansoh/NiKang, plus COVID-19 deals in brief and more.
Cash-Rich PureTech Displays Resilience In Troubled Times
PureTech said it finished 2019 with healthy finances and a promising pipeline which analysts said should offer positive catalysts for the UK group’s stock in 2020.
ResTORbio Pins Hopes On Parkinson’s After Failed CSRI Study
Company terminates studies of its TORC1 blocker after it fails to prevent respiratory illness in elderly patients with clinically symptomatic respiratory illness (CSRI). ResTORbio is hoping the same drug will be effective in Parkinson’s disease.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.